Skip to main content
. 2022 Jul 18;40(35):4048–4059. doi: 10.1200/JCO.22.00602

FIG 3.

FIG 3.

(A) OS in all FLT3mut patients treated at any dose (n = 56). (B) OS in FLT3mut patients who did (n = 35) or did not (n = 21) receive prior treatment with a FLT3 TKI. (C) OS in FLT3mut patients who did (n = 17) or did not (n = 39) receive alloSCT after VenGilt. alloSCT, allogeneic stem-cell transplantation; Gilt, gilteritinib; NR, not reached; OS, overall survival; TKI, tyrosine kinase inhibitor; Ven, venetoclax.